专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004108065A3 HEPARANASE ACTIVITY NEUTRALIZING ANTI- HEPARANASE MONOCLONAL ANTIBODY AND OTHER ANTI-HEPARANASE ANTIBODIES 审中-公开
标题翻译：抗HEPARANASE单克隆抗体和其他抗HEPARANASE抗体的HEPARANASE活性中和
公开(公告)号：WO2004108065A3
公开(公告)日：2007-01-25
申请号：PCT/IL2004000477
申请日：2004-06-03
申请人： INSIGHT BIOPHARMACEUTICALS LTD , HADASIT MED RES SERVICE , YACOBY-ZEEVI ORON , PERETZ TUVIA , MIRON DAPHNA , SHLOMI YINON , PECKER IRIS , AYAL-HERSHKOVITZ MATY , FEINSTEIN ELENA , VAN GELDER JOEL M , VLODAVSKY ISRAEL , FRIEDMANN YAEL
发明人： YACOBY-ZEEVI ORON , PERETZ TUVIA , MIRON DAPHNA , SHLOMI YINON , PECKER IRIS , AYAL-HERSHKOVITZ MATY , FEINSTEIN ELENA , VAN GELDER JOEL M , VLODAVSKY ISRAEL , FRIEDMANN YAEL
IPC分类号： A61K39/395 , A61K20060101 , A61P35/00 , A61P37/02 , C07K16/00 , C07K16/40 , C12N1/15 , C12N1/21 , C12N5/12 , C12N15/56 , C12P21/08 , C12Q1/34 , G01N33/53 , G01N33/68
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/73 , C07K2317/76 , C12Q1/34 , G01N33/6893
摘要： Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.
摘要翻译：公开了特异性抗肝素酶抗体，其特异性结合肝素酶与具有与乙酰肝素酶具有序列同源性的乙酰肝素酶，其可用于治疗和诊断与肝素酶催化活性相关的病症，用于纯化乙酰肝素酶和用于乙酰肝素酶相关病症中的药物开发。

2. 发明申请

WO2012118910A2 COMPOSITIONS AND METHODS FOR TREATING LUNG DISEASE AND INJURY 审中-公开
标题翻译：用于治疗肺部疾病和伤害的组合物和方法
公开(公告)号：WO2012118910A2
公开(公告)日：2012-09-07
申请号：PCT/US2012027169
申请日：2012-03-01
申请人： QUARK PHARMACEUTICALS INC , UNIV WASHINGTON , GELMAN ANDREW E , FEINSTEIN ELENA , ADAMSKY SVETLANA , METT IGOR , KALINSKI HAGAR , AVKIN-NACHUM SHARON
发明人： GELMAN ANDREW E , FEINSTEIN ELENA , ADAMSKY SVETLANA , METT IGOR , KALINSKI HAGAR , AVKIN-NACHUM SHARON
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/321 , C12N2310/344 , C12N2310/3521
摘要： Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising down-regulating the TLR2 gene or both the TLR2 gene and TLR4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury.
摘要翻译：本文公开了治疗哺乳动物肺部疾病，病症和损伤的治疗方法，包括治疗急性呼吸窘迫综合征（ARDS），急性肺损伤，肺纤维化（特发性），博来霉素诱导的肺纤维化，机械通气机诱发的肺损伤，慢性阻塞性肺疾病（COPD），慢性支气管炎，肺气肿，肺移植后闭塞性细支气管炎和肺移植引起的急性移植物功能障碍，包括治疗，预防或预防原发性移植物衰竭，缺血再灌注损伤，再灌注损伤，再灌注水肿，同种异体移植功能障碍，肺再植入反应，肺移植后闭塞性细支气管炎和/或器官移植后的原发性移植物功能障碍（PGD），特别是肺移植，包括下调TLR2基因或TLR2基因和TLR4基因。本文提供了用于治疗肺部疾病，病症和损伤的组合物，方法和试剂盒。

3. 发明申请

WO2004100759A3 ENDO 180 RECEPTOR FOR DIAGNOSIS AND TREATMENT 审中-公开
标题翻译：第180号接受诊断和治疗的受试者
公开(公告)号：WO2004100759A3
公开(公告)日：2009-03-12
申请号：PCT/IL2004000423
申请日：2004-05-18
申请人： QUARK BIOTECH INC , MOR ORNA , FEINSTEIN ELENA , FAERMAN ALEXANDER
发明人： MOR ORNA , FEINSTEIN ELENA , FAERMAN ALEXANDER
IPC分类号： G01N33/53 , A61B20060101 , C07H21/04 , C12P21/06 , G01N33/50 , G01N33/68
CPC分类号： G01N33/5032 , G01N33/6872 , G01N2333/4724 , G01N2333/78
摘要： This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO 180 modulators in treatment of disease.
摘要翻译：本申请涉及鉴定能够调节人ENDO180受体活性的化合物的方法，该方法包括以下步骤：在不存在或存在下测量ENDO180受体与ENDO180受体在体内特异性相互作用的相互作用因子的结合的化合物，并确定ENDO180受体与相互作用体的结合是否受化合物的影响。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化的药物中的用途。本申请还涉及使用ENDO 180调节剂治疗疾病。

4. 发明申请

WO2007141796A2 THERAPEUTIC USES OF INHIBITORS OF RTP801L 审中-公开
标题翻译： RTP801L抑制剂的治疗用途
公开(公告)号：WO2007141796A2
公开(公告)日：2007-12-13
申请号：PCT/IL2007000695
申请日：2007-06-07
申请人： QUARK PHARMACEUTICALS INC , FEINSTEIN ELENA , METT IGOR
发明人： FEINSTEIN ELENA , METT IGOR
IPC分类号： A61K48/00
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/31 , C12N2310/3521
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.
摘要翻译：本发明提供了基于RTP801L基因和/或蛋白质的抑制来治疗微血管病症，眼睛疾病呼吸系统疾病和听力障碍的新型分子，组合物，方法和用途。

5. 发明申请

WO2006131925A3 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2006131925A3
公开(公告)日：2007-08-02
申请号：PCT/IL2006000671
申请日：2006-06-08
申请人： QUARK BIOTECH INC , MOR ORNA , FEINSTEIN ELENA
发明人： MOR ORNA , FEINSTEIN ELENA
IPC分类号： C07H21/04 , A01N43/04 , A61K31/70 , A61K49/04 , C12P21/06 , C12Q1/68
CPC分类号： C12N15/1137 , C12N2310/14 , C12Y203/02013
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a gene of the TGase family at post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from fibrotic disease such as kidney and liver fibrosis and ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective amount so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGase polypeptides.
摘要翻译：本发明涉及在转录后水平下调TGase家族基因表达的双链化合物，优选寡核糖核苷酸。本发明还涉及包含该化合物或能够表达寡核糖核苷酸的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肾脏和肝纤维化和眼瘢痕的患者的方法，其包括以治疗有效量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用对TGase多肽的抗体来治疗纤维化和其它疾病。

6. 发明申请

WO2006092795A3 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF OCULAR SCARRING AND OTHER FIBROTIC CONDITIONS 审中-公开
标题翻译：用于治疗眼科疾病和其他纤维性疾病的低分子量化学物质及其使用方法
公开(公告)号：WO2006092795A3
公开(公告)日：2007-03-01
申请号：PCT/IL2006000285
申请日：2006-03-01
申请人： QBI ENTPR LTD , FEINSTEIN ELENA , MOR ORNA
发明人： FEINSTEIN ELENA , MOR ORNA
IPC分类号： A61K31/70 , A61K39/00 , C07H21/02 , C07H21/04 , C12Q1/68
CPC分类号： C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/32
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human MMP gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to MMP polypeptide.
摘要翻译：本发明涉及在转录后水平下调人MMP基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼瘢痕的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用MMP多肽的抗体来治疗纤维化和其它疾病。

7. 发明申请

WO02086084B1 SEQUENCE CHARACTERISTICS OF BLADDER CANCER 审中-公开
标题翻译：乳腺癌的序列特征
公开(公告)号：WO02086084B1
公开(公告)日：2003-11-20
申请号：PCT/US0212774
申请日：2002-04-04
申请人： QUARK BIOTECH INC , FEINSTEIN ELENA , MOR ORNA
发明人： FEINSTEIN ELENA , MOR ORNA
IPC分类号： C12Q1/68 , C07H21/04 , C12P19/34 , G01N33/53
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158
摘要： There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering a patient a therapeutically effective amount of chemical compound are also provided.
摘要翻译：提供了一种通过分析来自患者的组织样品中至少一种表达基因的存在来诊断患者膀胱癌的存在的方法，其中所表达的基因的存在指示膀胱癌。本发明还提供了表达膀胱癌的多核苷酸序列。还提供了膀胱癌的标记物。还提供了通过筛选至少一种表达基因的存在来诊断膀胱癌的方法，其中表达的基因的存在指示膀胱癌。还提供了通过给予患者治疗有效量的化合物来治疗和调节膀胱癌相关病变的方法。

8. 发明申请

WO02086084A2 SEQUENCE CHARACTERISTICS OF BLADDER CANCER 审中-公开
标题翻译：乳腺癌的序列特征
公开(公告)号：WO02086084A2
公开(公告)日：2002-10-31
申请号：PCT/US0212774
申请日：2002-04-04
申请人： QUARK BIOTECH INC , FEINSTEIN ELENA , MOR ORNA
发明人： FEINSTEIN ELENA , MOR ORNA
IPC分类号： C12Q1/68 , C12N
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158
摘要： There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering a patient a therapeutically effective amount of chemical compound are also provided.
摘要翻译：提供了一种通过分析来自患者的组织样品中至少一种表达基因的存在来诊断患者膀胱癌的存在的方法，其中所表达的基因的存在指示膀胱癌。本发明还提供了表达膀胱癌的多核苷酸序列。还提供了膀胱癌的标记物。还提供了通过筛选至少一种表达基因的存在来诊断膀胱癌的方法，其中表达的基因的存在指示膀胱癌。还提供了通过给予患者治疗有效量的化合物来治疗和调节膀胱癌相关病变的方法。

9. 发明申请

WO2013067076A3 METHODS AND COMPOSITIONS FOR NEUROPROTECTION 审中-公开
标题翻译：神经保护的方法和组合
公开(公告)号：WO2013067076A3
公开(公告)日：2013-07-04
申请号：PCT/US2012062894
申请日：2012-11-01
申请人： QUARK PHARMACEUTICALS INC , FEINSTEIN ELENA
发明人： FEINSTEIN ELENA
IPC分类号： C12N15/113 , A61K31/713 , A61P27/16 , C12N9/64
CPC分类号： C12N15/1137 , A61K9/0046 , A61K31/713 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/30 , C12N2320/32 , C12Y304/22017 , C12Y304/22055 , C12Y306/03 , C12Y306/05002 , C12N2310/3521
摘要： Disclosed herein are methods and kits useful for providing neuroprotection to neurons in the inner ear and to methods of treating inner ear diseases and disorders, including tinnitus and Mnire's disease.
摘要翻译：本文公开了可用于向内耳中的神经元提供神经保护的方法和试剂盒以及治疗内耳疾病和障碍的方法，包括耳鸣和奈米氏病。

10. 发明申请

WO2011072082A3 MODULATION OF HSP47 EXPRESSION 审中-公开
标题翻译： HSP47表达调控
公开(公告)号：WO2011072082A3
公开(公告)日：2011-08-18
申请号：PCT/US2010059578
申请日：2010-12-08
申请人： NITTO DENKO CORP , QUARK PHARMACEUTICALS INC , JIN XIAOMEI , YU LEI , TAKAHASHI HIROKAZU , TANAKA YASUNOBU , NIITSU YOSHIRO , FEINSTEIN ELENA , AVKIN-NACHUM SHARON , KALINSKI HAGAR , METT IGOR , ERLICH SHAI , SQUIERS ELIZABETH C
发明人： JIN XIAOMEI , YU LEI , TAKAHASHI HIROKAZU , TANAKA YASUNOBU , NIITSU YOSHIRO , FEINSTEIN ELENA , AVKIN-NACHUM SHARON , KALINSKI HAGAR , METT IGOR , ERLICH SHAI , SQUIERS ELIZABETH C
IPC分类号： A61K31/7088 , C07H21/00
CPC分类号： C12N15/113 , A61K31/713 , C12N2310/11 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/317 , C12N2310/32 , C12N2310/321 , C12N2310/33 , C12N2310/531 , C12N2320/30 , C12N2310/3521
摘要： Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.
摘要翻译：本文提供用于调节靶基因，特别是热休克蛋白47（hsp47）的表达的组合物，方法和试剂盒。组合物，方法和试剂盒可以包括核酸分子（例如，短干扰核酸（siNA），短干扰RNA（siRNA），双链RNA（dsRNA），微RNA（miRNA）或短发夹RNA（shRNA））），其调节编码hsp47的基因，例如编码人hsp47的基因。本文公开的组合物和方法也可用于治疗与hsp47相关的病症和病症，例如肝纤维化，肺纤维化，腹膜纤维化和肾纤维化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式